Hicks, Muse & Co. v. Brandt

136 F.3d 45, 216 B.R. 45
CourtCourt of Appeals for the First Circuit
DecidedFebruary 13, 1998
Docket97-1381
StatusPublished
Cited by79 cases

This text of 136 F.3d 45 (Hicks, Muse & Co. v. Brandt) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hicks, Muse & Co. v. Brandt, 136 F.3d 45, 216 B.R. 45 (1st Cir. 1998).

Opinion

*47 CYR, Senior Circuit Judge.

The question presented on appeal is whether the bankruptcy court abused its discretion by approving a settlement between the chapter 7 trustee for Healtheo International, Inc. and a consortium of banks (“the Bank Group”) which financed a prepetition leveraged buy-out (“LBO”) of Healtheo by appellants Hicks Muse & Co., Inc. and its coinvestors (collectively: “Hicks Muse”). We affirm.

I

BACKGROUND

Appellant Hicks Muse financed the 1991 LBO with a $50 million term loan and a $65 million revolving credit facility from the Bank Group, secured by liens on all Healtheo assets. Healtheo filed its chapter 11 petition in June 1993 and continued to operate as a debtor-in-possession. Three months later an interim trustee was appointed and the reorganization was converted to a chapter 7 liquidation.

By the time the chapter 7 trustee (“Trustee”) was appointed approximately one month later, Healthco’s assets already were undergoing liquidation by the interim trustee, subject to bankruptcy court approval. In the chapter 11 schedules the Healtheo assets were valued at $149 million, but were later assigned a liquidation value between $33 and $66 million.

After obtaining relief from the automatic stay, see Bankruptcy Code § 362, 11 U.S.C. § 362, the Bank Group proceeded to liquidate its Healtheo collateral, having agreed to provide the Trustee with “full, complete, and detailed aceounting[s]” of the liquidation on a monthly basis. Over the ensuing year the Trustee lodged several complaints, with the Bank Group and the bankruptcy court, that the promised accountings had not been forthcoming or were deficient. Eventually the Bank Group submitted a thirty-page accounting pursuant to court order and provided the Trustee with thirty cartons of raw invoices generated during the collateral liquidation process.

After declining to incur “the incredible cost ... of ... go[ing] through the[se] records item by item,” the Trustee commenced an adversary proceeding against Hicks Muse and the Bank Group, asserting two principal claims. First, since the LBO had left Healtheo insolvent, the Trustee claimed that the $115 million lien obtained by the Bank Group on the Healtheo assets constituted a voidable fraudulent transfer (hereinafter: “the fraudulent transfer claim”). See Bankruptcy Code § 544(b), 11 U.S.C. § 544(b). Second, the Trustee claimed that the Bank Group had liquidated its Healtheo collateral in a “commercially unreasonable” manner, see Mass. Gen. Laws Ann. ch. 106, § 9-504(3) (“UCC”), which yielded only $50-60 million on assets with an estimated value (per chapter 11 schedules) exceeding $149 million (hereinafter: “the UCC claim”).

The Trustee subsequently proposed to dismiss both the fraudulent transfer claim and the UCC claim, see Fed. R. Bankr.P. 9019(a); 1 see also Fed. R. Bankr.P. 9014 (contested matters), in return for the Bank Group’s agreement to pay the chapter 7 estate $9 million in cash, waive roughly $1 million in allowed priority claims against the chapter 7 estate and a deficiency claim estimated at $35 million, and assign to the Trustee any LBO-related claims the Bank Group might have against third parties, including nonsettling defendants in the adversary proceeding. 2 The Trustee in turn agreed not to oppose the $50-60 million secured claim asserted by the Bank Group against the Healtheo collateral. Several codefendants, including Hicks Muse, objected to the settlement.

*48 At the hearing before the bankruptcy court, the Trustee contended that the proposed $45 million settlement would serve the “best interests” of the chapter 7 estate, see Kowal v. Malkemus (In re Thompson), 965 F.2d 1136, 1141 n. 5, 1145 (1st Cir.1992), for two reasons. First, the Trustee pointed out that the $45 million offer would return the chapter 7 estate ninety percent of the $50 million estimated maximum litigated value of the fraudulent transfer claim, without litigation risk. Second, the Trustee noted several factors central to his assessment that the UCC claim, fully litigated, could generate only minimal value for the chapter 7 estate. See infra Section II.B.l. The bankruptcy court approved the proposed settlement with one pertinent modification. 3

On intermediate appeal to the district court, Hicks Muse challenged the bankruptcy court finding that the settlement between the Trustee and the Bank Group had been negotiated in “good faith.” The district court ruled the “good faith” test immaterial under the “best interests” standard applicable under Bankruptcy Rule 9019, and opined that a finding of “good faith” might be misperceived by state courts as a basis for barring Hicks Muse from pursuing its state-law contribution claim against the Bank Group. In all other respects the bankruptcy court order was affirmed by the district court.

II

DISCUSSION

A. Appellate Jurisdiction

The Trustee contends that the appeal is moot because Hicks Muse knowingly disregarded his warning that the settlement would be consummated promptly absent a timeous stay of the bankruptcy court order approving the settlement. As Hicks Muse sought no stay, the Bank Group promptly disbursed $9 million to the Trustee, from which $2.5 million has since been used to defray professional fees. Thereafter, all claims in the adversary proceeding against the Bank Group were dismissed with prejudice.

1. Equitable Mootness

The “equitable mootness” doctrine imports both “equitable” and “pragmatic” limitations upon our appellate jurisdiction over bankruptcy appeals. See Institui Pasteur v. Cambridge Biotech Corp. (In re Cambridge Biotech Corp.), 104 F.3d 489, 492 n. 5 (1st Cir.), cert. denied, —U.S.-, 117 S.Ct. 2511, 138 L.Ed.2d 1014 (1997); Rochman v. Northeast Utils. Serv. Group (In re Public Serv. Co. of N.H.), 963 F.2d 469, 471 (1st Cir.1992).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Boy Scouts of America and Delaware BSA LLC v.
137 F.4th 126 (Third Circuit, 2025)
Said Taleb v. Wendy Lewis
Sixth Circuit, 2023
Muhammed Al-Idrisi
D. Massachusetts, 2021
Desmond v. Edrissi
D. Massachusetts, 2021
In re CS Mining, LLC
574 B.R. 259 (D. Utah, 2017)
In re Grove Instruments, Inc.
573 B.R. 307 (D. Massachusetts, 2017)
In re Boddie
569 B.R. 297 (S.D. Ohio, 2017)
Selene Finance LP v. Brown (In re Brown)
563 B.R. 451 (D. Massachusetts, 2017)
Said Adeli v. Christopher Barclay
834 F.3d 1036 (Ninth Circuit, 2016)
Tribune Media Company v.
799 F.3d 272 (Third Circuit, 2015)
In Re: BGI, Inc.
Second Circuit, 2014
Ingaseosas International Co. v. Aconcagua Investing LTD.
479 F. App'x 955 (Eleventh Circuit, 2012)
In Re Chicago Investments, LLC
470 B.R. 32 (D. Massachusetts, 2012)
Marmarinos v. DeGiacomo (In re Marmarinos)
464 B.R. 498 (First Circuit, 2012)
In Re American Cartage, Inc.
656 F.3d 82 (First Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
136 F.3d 45, 216 B.R. 45, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hicks-muse-co-v-brandt-ca1-1998.